Skip to main content

Table 3 Results from multivariate linear regression final models to identify factors associated with the relative change in bilirubin over the first 12 weeks of ATV treatment

From: Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir

 

Relative change in bilirubin

95% Confidence Interval

P-value

Main model – with HCV seropositivity

   

Baseline ALP (/5 IU increase)

0.99

0.98, 1.00

0.04

TDF use at baseline

0.86

0.72, 1.00

0.10

HCV seropositivity

0.80

0.66, 0.97

0.02

Baseline bilirubin

0.98

0.96, 1.00

0.05

Sensitivity analysis 1 – with methadone use

   

ALP at baseline (/5 IU increase)

0.99

0.98, 1.00

0.01

TDF use at baseline

0.83

0.70, 0.99

0.04

Methadone use

0.77

0.65, 0.92

0.01

Baseline bilirubin

0.98

0.96, 1.00

0.04

Sensitivity analysis 2 – with IVDU

   

ALP at baseline (/5 IU increase)

0.99

0.98, 1.00

0.02

TDF use at baseline

0.83

0.70, 1.00

0.05

IVDU

0.85

0.70, 1.00

0.08

Baseline bilirubin

0.98

0.96, 1.00

0.02